BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31282240)

  • 1. HIV portends a poor prognosis in myelodysplastic syndromes.
    Kaner JD; Thibaud S; Jasra S; Wang Y; Janakiram M; Sharma A; Sridharan A; Elias H; Polineni R; Assal A; Weiss L; Braunschweig I; Steidl U; Pradhan K; Shastri A; Chaitowitz M; Zingman B; Will B; Mantzaris I; Verma A
    Leuk Lymphoma; 2019 Dec; 60(14):3529-3535. PubMed ID: 31282240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
    Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
    Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection.
    Takahashi K; Yabe M; Shapira I; Pierce S; Garcia-Manero G; Varma M
    Leuk Res; 2012 Nov; 36(11):1376-9. PubMed ID: 22917767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
    Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
    Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
    Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients.
    Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z
    Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
    Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
    Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
    Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
    Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
    Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
    Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Huang HH; Chen FY; Chou WC; Hou HA; Ko BS; Lin CT; Tang JL; Li CC; Yao M; Tsay W; Hsu SC; Wu SJ; Chen CY; Huang SY; Tseng MH; Tien HF; Chen RH
    BMC Cancer; 2019 Jun; 19(1):617. PubMed ID: 31234830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis.
    Maschek H; Kaloutsi V; Rodriguez-Kaiser M; Werner M; Choritz H; Mainzer K; Dietzfelbinger M; Georgii A
    Ann Hematol; 1993 Mar; 66(3):117-22. PubMed ID: 8471656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
    Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
    Nazha A; Komrokji R; Meggendorfer M; Jia X; Radakovich N; Shreve J; Hilton CB; Nagata Y; Hamilton BK; Mukherjee S; Al Ali N; Walter W; Hutter S; Padron E; Sallman D; Kuzmanovic T; Kerr C; Adema V; Steensma DP; Dezern A; Roboz G; Garcia-Manero G; Erba H; Haferlach C; Maciejewski JP; Haferlach T; Sekeres MA
    J Clin Oncol; 2021 Nov; 39(33):3737-3746. PubMed ID: 34406850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.